Revenue declined 10% year-on-year, compared with expectations of a 5% decline, while EBITDA fell 34% against the estimated 16% drop. Net profit declined 39%, significantly worse than the 22% decline expected.
EBITDA margin contracted by around 760 basis points to 21.5%, compared with estimates of 24%. The agrochemicals business saw a 10% year-on-year decline in revenue, while margins also weakened significantly. Losses in the pharma segment widened from a year earlier.
PI Industries said exports continue to operate in a challenging environment. The company plans to launch 4-5 new molecules in FY27, while its pharma business remains focused on accelerating growth across Brazil, Mexico, Europe and the US.The company maintained its FY27 revenue growth guidance of low-single-digit growth. Its order book stood at around $1.2 billion, broadly stable sequentially.
